These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 12060610)

  • 1. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
    Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
    Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
    Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N
    Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
    Idenoue S; Hirohashi Y; Torigoe T; Sato Y; Tamura Y; Hariu H; Yamamoto M; Kurotaki T; Tsuruma T; Asanuma H; Kanaseki T; Ikeda H; Kashiwagi K; Okazaki M; Sasaki K; Sato T; Ohmura T; Hata F; Yamaguchi K; Hirata K; Sato N
    Clin Cancer Res; 2005 Feb; 11(4):1474-82. PubMed ID: 15746049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
    Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
    Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients.
    Yang D; Nakao M; Shichijo S; Sasatomi T; Takasu H; Matsumoto H; Mori K; Hayashi A; Yamana H; Shirouzu K; Itoh K
    Cancer Res; 1999 Aug; 59(16):4056-63. PubMed ID: 10463607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.
    Kobayashi J; Torigoe T; Hirohashi Y; Idenoue S; Miyazaki A; Yamaguchi A; Hiratsuka H; Sato N
    J Transl Med; 2009 Jan; 7():1. PubMed ID: 19123955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes.
    Tahara K; Takesako K; Sette A; Celis E; Kitano S; Akiyoshi T
    Clin Cancer Res; 1999 Aug; 5(8):2236-41. PubMed ID: 10473111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide.
    Nishiyama T; Tachibana M; Horiguchi Y; Nakamura K; Ikeda Y; Takesako K; Murai M
    Clin Cancer Res; 2001 Jan; 7(1):23-31. PubMed ID: 11205913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
    Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs.
    Gomi S; Nakao M; Niiya F; Imamura Y; Kawano K; Nishizaka S; Hayashi A; Sobao Y; Oizumi K; Itoh K
    J Immunol; 1999 Nov; 163(9):4994-5004. PubMed ID: 10528204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides.
    Schmitz M; Diestelkoetter P; Weigle B; Schmachtenberg F; Stevanovic S; Ockert D; Rammensee HG; Rieber EP
    Cancer Res; 2000 Sep; 60(17):4845-9. PubMed ID: 10987296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma.
    Nishizaka S; Gomi S; Harada K; Oizumi K; Itoh K; Shichijo S
    Cancer Res; 2000 Sep; 60(17):4830-7. PubMed ID: 10987294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a promiscuous HLA DR-restricted T-cell epitope derived from the inhibitor of apoptosis protein survivin.
    Piesche M; Hildebrandt Y; Zettl F; Chapuy B; Schmitz M; Wulf G; Trümper L; Schroers R
    Hum Immunol; 2007 Jul; 68(7):572-6. PubMed ID: 17584578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.
    Homma S; Harada M; Yano H; Ogasawara S; Shichijo S; Matsueda S; Komatsu N; Shomura H; Maeda Y; Sato Y; Todo S; Itoh K
    Int J Oncol; 2006 Sep; 29(3):577-87. PubMed ID: 16865273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
    Kontani K; Teramoto K; Ozaki Y; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Yokomise H; Ohkubo I
    Int J Oncol; 2004 Dec; 25(6):1537-42. PubMed ID: 15547688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.
    Azuma K; Sasada T; Takedatsu H; Shomura H; Koga M; Maeda Y; Yao A; Hirai T; Takabayashi A; Shichijo S; Itoh K
    Clin Cancer Res; 2004 Oct; 10(19):6695-702. PubMed ID: 15475460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
    Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
    Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
    Miyazaki A; Kobayashi J; Torigoe T; Hirohashi Y; Yamamoto T; Yamaguchi A; Asanuma H; Takahashi A; Michifuri Y; Nakamori K; Nagai I; Sato N; Hiratsuka H
    Cancer Sci; 2011 Feb; 102(2):324-9. PubMed ID: 21143701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
    Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T
    Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.
    Umano Y; Tsunoda T; Tanaka H; Matsuda K; Yamaue H; Tanimura H
    Br J Cancer; 2001 Apr; 84(8):1052-7. PubMed ID: 11308253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.